Neurocrine Biosciences, Inc. (NBIX) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Neurocrine Biosciences financial statements at a glance

Neurocrine Biosciences reported revenue of $2.86 billion for fiscal year 2025 (ended December 31, 2025), up 21.2% from fiscal year 2024. Net income was $478.60 million, a net margin of 16.7%, and diluted earnings per share were $4.67.

At the end of fiscal year 2025 it had total assets of $4.63 billion, total liabilities of $1.38 billion and shareholders' equity of $3.25 billion, with cash and short-term investments of $1.48 billion and total debt of $415.30 million.

Its operations brought in $782.70 million of cash; capital spending was $34.00 million, leaving free cash flow of $748.70 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

NBIX logo

Neurocrine Biosciences, Inc.

NBIXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
2.86B
Prev Year: 2.36B
YoY: +21.2%
Operating Revenue
2.86B
Prev Year: 2.36B
YoY: +21.2%
Normalized EBITDA
688.00M
Prev Year: 701.10M
YoY: -1.9%
Tax Rate for Calcs
0.322
Prev Year: 0.3
YoY: +7.2%
Tax Effect of Unusual Items
-6.88M
Prev Year: -18.28M
YoY: +62.4%
Total Operating Income as Reported
619.10M
Prev Year: 570.50M
YoY: +8.5%
Other Income Expense
-21.40M
Prev Year: -61.40M
YoY: +65.1%
Special Income Charges
-17.40M
Prev Year: -14.70M
YoY: -18.4%
Other Special Charges
17.40M
Prev Year: 14.70M
YoY: +18.4%
Gain on Sale of Securities
-4.00M
Prev Year: -46.70M
YoY: +91.4%
Cost of Revenue
52.10M
Prev Year: 34.00M
YoY: +53.2%
Gross Profit
2.81B
Prev Year: 2.32B
YoY: +21.1%
Operating Expense
2.17B
Prev Year: 1.74B
YoY: +24.8%
Selling General and Administrative
1.16B
Prev Year: 1.01B
YoY: +14.5%
Research and Development
1.02B
Prev Year: 731.10M
YoY: +38.9%
Operating Income
636.50M
Prev Year: 583.00M
YoY: +9.2%
Net Non Operating Interest Income Expense
90.30M
Prev Year: -35.60M
YoY: +353.7%
Non-operating Interest Income
90.30M
Prev Year: 91.00M
YoY: -0.8%
Pre-tax Income
705.40M
Prev Year: 486.00M
YoY: +45.1%
Provision for Income Taxes
226.80M
Prev Year: 144.70M
YoY: +56.7%
Net Income Common Stockholders
478.60M
Prev Year: 341.30M
YoY: +40.2%
Net Income
478.60M
Prev Year: 341.30M
YoY: +40.2%
Net Income Including Non-Controlling Interests
478.60M
Prev Year: 341.30M
YoY: +40.2%
Net Income from Continuing Operations
478.60M
Prev Year: 341.30M
YoY: +40.2%
Diluted NI Available to Com Stockholders
478.60M
Prev Year: 341.30M
YoY: +40.2%
Basic EPS
4.81
Prev Year: 3.4
YoY: +41.5%
Diluted EPS
4.67
Prev Year: 3.29
YoY: +41.9%
Weighted Average Shares (basic)
99.50M
Prev Year: 100.40M
YoY: -0.9%
Weighted Average Shares (diluted)
102.50M
Prev Year: 103.70M
YoY: -1.2%
Total Expenses
2.22B
Prev Year: 1.77B
YoY: +25.6%
Net Income from Continuing and Discontinued Operation
478.60M
Prev Year: 341.30M
YoY: +40.2%
Normalized Income
493.12M
Prev Year: 384.42M
YoY: +28.3%
Interest Income
90.30M
Prev Year: 91.00M
YoY: -0.8%
Net Interest Income
90.30M
Prev Year: -35.60M
YoY: +353.7%
EBIT
636.50M
Prev Year: 612.60M
YoY: +3.9%
EBITDA
666.60M
Prev Year: 639.70M
YoY: +4.2%
Interest Expense
-
Prev Year: 126.60M
Reconciled Cost of Revenue
52.10M
Prev Year: 34.00M
YoY: +53.2%
Reconciled Depreciation
30.10M
Prev Year: 27.10M
YoY: +11.1%
Net Income from Continuing Operation Net Minority Interest
478.60M
Prev Year: 341.30M
YoY: +40.2%
Total Unusual Items Excluding Goodwill
-21.40M
Prev Year: -61.40M
YoY: +65.1%
Total Unusual Items
-21.40M
Prev Year: -61.40M
YoY: +65.1%
Values in USD

Neurocrine Biosciences key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$2.9B$2.4B$1.9B$1.5B$1.1B
Gross profit$2.8B$2.3B$1.9B$1.5B$1.1B
Operating income$636.5M$583.0M$394.8M$249.0M$207.8M
Net income$478.6M$341.3M$249.7M$154.5M$89.6M
Diluted EPS$4.67$3.29$2.47$1.56$0.92
Total assets$4.6B$3.7B$3.3B$2.4B$2.1B
Total liabilities$1.4B$1.1B$1.0B$660.9M$698.5M
Shareholders' equity$3.3B$2.6B$2.2B$1.7B$1.4B
Cash and short-term investments$1.5B$1.1B$1.0B$989.3M$711.3M
Total debt$415.3M$455.1M$428.4M$262.9M$440.4M
Operating cash flow$782.7M$595.4M$389.9M$339.4M$256.5M
Capital spending$34.0M$38.2M$28.3M$16.5M$23.4M
Free cash flow$748.7M$557.2M$361.6M$322.9M$233.1M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Neurocrine Biosciences's revenue in fiscal year 2025?

$2.86 billion, up 21.2% from $2.36 billion in fiscal year 2024.

How much profit does Neurocrine Biosciences make?

Neurocrine Biosciences reported net income of $478.60 million for fiscal year 2025 (16.7% of revenue); operating income was $636.50 million.

How much cash and debt does Neurocrine Biosciences have?

At the end of fiscal year 2025: cash and short-term investments of $1.48 billion and total debt of $415.30 million.

What is Neurocrine Biosciences's free cash flow?

$748.70 million in fiscal year 2025 (operating cash flow of $782.70 million minus capital spending of $34.00 million).

MoreNeurocrine Biosciences stock overviewNeurocrine Biosciences executive teamNeurocrine Biosciences shareholdersNeurocrine Biosciences revenue by segment
RelatedBiological Product (except Diagnostic) Manufacturing industryManufacturing sectorargenx financialsBiogen financialsJazz Pharmaceuticals financialsAxsome Therapeutics (AXSM)Praxis Precision Medicines (PRAX)Alkermes (ALKS)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube